TR200200717T2 - Therapeutic quinazoline derivatives. - Google Patents

Therapeutic quinazoline derivatives.

Info

Publication number
TR200200717T2
TR200200717T2 TR2002/00717T TR200200717T TR200200717T2 TR 200200717 T2 TR200200717 T2 TR 200200717T2 TR 2002/00717 T TR2002/00717 T TR 2002/00717T TR 200200717 T TR200200717 T TR 200200717T TR 200200717 T2 TR200200717 T2 TR 200200717T2
Authority
TR
Turkey
Prior art keywords
therapeutic
quinazoline derivatives
aurora
prodrug
kinase
Prior art date
Application number
TR2002/00717T
Other languages
Turkish (tr)
Inventor
Austen Mortlock Andrew
John Keen Nicholas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR200200717T2 publication Critical patent/TR200200717T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Formül (I)' e ait bilesik ya da bunun bir tuzu, esteri, amiti ya da ön ilaci. Bu bilesikler, aurora 2 kinazi önler ve bunlar, kanser gibi proliferativ hastaliklarin tedavisine yönelik preparasyonunda faydalidir.Compound of formula (I) or a salt, ester, amide or prodrug thereof. These compounds prevent aurora 2 kinase and are useful in the preparation for the treatment of proliferative diseases such as cancer.

TR2002/00717T 1999-09-21 2000-09-19 Therapeutic quinazoline derivatives. TR200200717T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9922171.5A GB9922171D0 (en) 1999-09-21 1999-09-21 Chemical compounds

Publications (1)

Publication Number Publication Date
TR200200717T2 true TR200200717T2 (en) 2002-06-21

Family

ID=10861217

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00717T TR200200717T2 (en) 1999-09-21 2000-09-19 Therapeutic quinazoline derivatives.

Country Status (24)

Country Link
US (1) US7235559B1 (en)
EP (1) EP1218355A1 (en)
JP (1) JP2003509500A (en)
KR (1) KR20020030123A (en)
CN (1) CN1391563A (en)
AR (1) AR025735A1 (en)
AU (1) AU762697B2 (en)
BG (1) BG106526A (en)
BR (1) BR0014137A (en)
CA (1) CA2384296A1 (en)
CO (1) CO5200783A1 (en)
CZ (1) CZ20021008A3 (en)
EE (1) EE200200118A (en)
GB (1) GB9922171D0 (en)
HK (1) HK1046685A1 (en)
HU (1) HUP0300205A3 (en)
IL (1) IL148496A0 (en)
IS (1) IS6310A (en)
NO (1) NO20021400L (en)
PL (1) PL354870A1 (en)
SK (1) SK3872002A3 (en)
TR (1) TR200200717T2 (en)
WO (1) WO2001021597A1 (en)
ZA (1) ZA200202232B (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL360439A1 (en) * 2000-06-28 2004-09-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
WO2002036587A2 (en) 2000-11-01 2002-05-10 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
JP2002293773A (en) * 2001-03-30 2002-10-09 Sumika Fine Chemicals Co Ltd Method for producing quinazoline derivative
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
WO2003035602A1 (en) * 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
IL162541A0 (en) * 2001-12-24 2005-11-20 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases
RS63204A (en) 2002-01-17 2006-10-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
AU2003257666A1 (en) * 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
KR101089462B1 (en) 2002-11-04 2011-12-07 아스트라제네카 아베 Quinazoline derivatives as src tyrosine kinase inhibitors
EP1625121B1 (en) 2002-12-20 2010-02-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AU2003299943A1 (en) * 2002-12-23 2004-07-22 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
AU2003290279A1 (en) * 2002-12-23 2004-07-14 Astrazeneca Ab Quinazoline derivatives
AU2003292435A1 (en) * 2002-12-23 2004-07-14 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
ES2290529T3 (en) 2002-12-24 2008-02-16 Astrazeneca Ab DERIVATIVES OF PHOSPHONOOXYQUINAZOLINE AND ITS PHARMACEUTICAL USE.
US20060058325A1 (en) * 2002-12-24 2006-03-16 Astrazeneca Ab Therapeutic quniazoline derivatives
CA2508921A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
AU2004232527A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Chemical compounds
ES2308182T3 (en) * 2003-06-02 2008-12-01 Astrazeneca Ab DERIVATIVES OF (3 - ((QUINAZOLIN-4-IL) AMINO) -1H-PIRAZOL-1-IL) ACETAMIDE AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER.
WO2004108710A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab 4-pyrimidinyl quinazoline derivatives for use in the treatment of tumours
WO2004108711A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyrazinil quinazoline derivatives for use in the treatment of tumours
WO2004108707A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyridazinil quinazoline derivatives for use in the treatment of tumours
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
MXPA06001767A (en) * 2003-08-14 2006-05-12 Array Biopharma Inc Quinazoline analogs as receptor tyrosine kinase inhibitors.
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
JP4638436B2 (en) 2003-09-26 2011-02-23 エグゼリクシス， インコーポレイテッド c-Met modulators and uses thereof
PT1678166E (en) * 2003-10-14 2009-10-30 Supergen Inc Protein kinase inhibitors
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
JP2007509985A (en) * 2003-10-31 2007-04-19 ニューロジェン・コーポレーション Capsaicin receptor agonist
US7632840B2 (en) 2004-02-03 2009-12-15 Astrazeneca Ab Quinazoline compounds for the treatment of hyperproliferative disorders
JP2007537238A (en) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク Pyrimidine derivatives for the treatment of abnormal cell proliferation
MXPA06013164A (en) 2004-05-14 2007-02-13 Pfizer Prod Inc Pyrimidines derivatives for the treatment of abnormal cell growth.
CA2566477A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
AR050948A1 (en) 2004-09-24 2006-12-06 Hoffmann La Roche DERIVATIVES OF FTALAZINONA; ITS OBTAINING AND ITS USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CANCER.
CN101072758B (en) 2004-10-12 2013-07-31 阿斯利康(瑞典)有限公司 Quinazoline derivatives
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006104971A1 (en) * 2005-03-28 2006-10-05 Bristol-Myers Squibb Company Atp competitive kinase inhibitors
EP1879894A1 (en) 2005-04-14 2008-01-23 F.Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009528336A (en) * 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ Quinoline derivatives
UY30183A1 (en) 2006-03-02 2007-10-31 Astrazeneca Ab QUINOLINE DERIVATIVES
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
WO2008095847A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
AU2008236670B2 (en) * 2007-04-05 2011-12-01 Amgen Inc. Aurora kinase modulators and method of use
CN101215274B (en) * 2007-12-27 2011-05-04 上海北卡医药技术有限公司 Technique for preparing N-substituted morpholines organic compounds
AU2009211523B2 (en) 2008-02-07 2014-03-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
JP2011515401A (en) 2008-03-20 2011-05-19 アムジエン・インコーポレーテツド Aurora kinase modulator and methods of use
JP5739802B2 (en) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ 4- (3-Chloro-2-fluoroanilino) -7-methoxy-6-{[1- (N-methylcarbamoylmethyl) piperidin-4-yl] oxy} quinazoline fumarate
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
EP2241565A1 (en) 2009-01-15 2010-10-20 Universität Leipzig Aurora kinase inhibitors compounds
TW201920110A (en) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 Pharmaceutical composition comprising malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide and use thereof
WO2010111063A1 (en) * 2009-03-21 2010-09-30 Ning Xi Amino ester derivatives, salts thereof and methods of use
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
CN103304489B (en) * 2012-03-16 2015-03-11 中国农业科学院兰州畜牧与兽药研究所 Pyrimidine benzamide compound and preparation and application thereof
WO2015036792A1 (en) 2013-09-16 2015-03-19 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
US10030004B2 (en) 2014-01-01 2018-07-24 Medivation Technologies Llc Compounds and methods of use
ES2899906T3 (en) 2015-07-06 2022-03-15 Alkermes Inc Bicyclic histone deacetylase inhibitors
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
EP3184507A1 (en) * 2015-12-22 2017-06-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Preparation of phenyl compounds
WO2018132533A1 (en) 2017-01-11 2018-07-19 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
CA3071861A1 (en) 2017-08-07 2019-02-14 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
CN110746398A (en) * 2019-10-18 2020-02-04 刘沛友 4-heterocyclic substituted quinazoline derivative and preparation method and application thereof
CN114436975B (en) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-trifluoromethyl-4-aminoquinazoline compound and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
AU3630100A (en) * 1999-03-19 2000-10-09 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof

Also Published As

Publication number Publication date
HK1046685A1 (en) 2003-01-24
CZ20021008A3 (en) 2002-06-12
KR20020030123A (en) 2002-04-22
US7235559B1 (en) 2007-06-26
BR0014137A (en) 2002-05-21
SK3872002A3 (en) 2002-12-03
NO20021400D0 (en) 2002-03-20
JP2003509500A (en) 2003-03-11
CN1391563A (en) 2003-01-15
ZA200202232B (en) 2003-08-27
IL148496A0 (en) 2002-09-12
WO2001021597A1 (en) 2001-03-29
GB9922171D0 (en) 1999-11-17
AU762697B2 (en) 2003-07-03
AR025735A1 (en) 2002-12-11
CO5200783A1 (en) 2002-09-27
EP1218355A1 (en) 2002-07-03
HUP0300205A3 (en) 2003-08-28
CA2384296A1 (en) 2001-03-29
EE200200118A (en) 2003-04-15
AU7301900A (en) 2001-04-24
BG106526A (en) 2002-10-31
PL354870A1 (en) 2004-03-08
HUP0300205A2 (en) 2003-05-28
NO20021400L (en) 2002-05-06
IS6310A (en) 2002-03-19

Similar Documents

Publication Publication Date Title
TR200200717T2 (en) Therapeutic quinazoline derivatives.
EA200500853A1 (en) 2,4,6-TRYZENACES OF PYRIMIDINES, WHICH ARE PHOSPHOTIDYLINOSITOL (PI) -3-KINASE INHIBITORS AND THEIR APPLICATION IN TREATMENT OF CANCER
TR200201505T2 (en) Pirazolopyrimidines as therapeutic agents
CY1114708T1 (en) PYRAZOLO-KINAZOLINE PRODUCERS, PROCEDURE FOR THEIR PREPARATION AND THEIR USE AS MICROSOFT
TR200102603T2 (en) Camptothecin derivatives with antitumor activity
AU7031500A (en) Therapeutic quinazoline compounds
ATE353888T1 (en) CHINAZOLINE DERIVATIVES
PL367682A1 (en) Dolastatin 10 derivatives
DE60001974D1 (en) DERIVATIVES OF FLAVONES, XANTHONES AND CUMARINES
TR199900336T2 (en) Tetrahydroquinoline derivatives as EAA antagonists.
ATE456952T1 (en) SOLUBLE TOPOISOMERASE POISONS
EE200000472A (en) Antineoplastic agents
DE60001586D1 (en) DIPHENYL-PIPERIDINE DERIVATIVES
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
IL151200A0 (en) Tricyclic imidazopyridine prodrug derivatives and pharmaceutical compositions containing the same
ATE424200T1 (en) SOLUBILIZED TOPOISOMERASE POISON AGENT
ATE390923T1 (en) TOPOISOMERASE TOXICANTS
EP1109560A4 (en) Compounds useful as aicarft inhibitors
ATE326451T1 (en) QUINAZOLINE DERIVATIVES AND THERAPEUTIC USES THEREOF
BR0309996A (en) Compound, pharmaceutical composition, method of treating or ameliorating proliferative diseases or conditions, use of a compound, and method of treating or ameliorating inflammatory diseases
GEP20032996B (en) Combinations of Protein Farnesyltransferase and HMG CoA Reductase Inhibitors, Pharmaceutical Compositions and Methods for Treatment
HUP0302629A2 (en) Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
YU46302A (en) Substituted pyrroles
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof